<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184951</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 03.01</org_study_id>
    <nct_id>NCT00184951</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients</brief_title>
  <official_title>Pharmacodynamics and Pharmacokinetics of Combined Use of Rosuvastatin (Crestor) and Lopinavir/Ritonavir (Kaletra) in HIV-infected Patients With Hyperlipidemia (ROSALKA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with&#xD;
      hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the effect of rosuvastatin on plasma lipids, lipoproteins, and endothelial&#xD;
      function in HIV-infected patients on stable lopinavir/ritonavir therapy and to evaluate the&#xD;
      safety of combined use of rosuvastatin and lopinavir/ritonavir. Also to determine the effect&#xD;
      of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin compared to historical&#xD;
      controls an to determine the effect of rosuvastatin on the pk of lopinavir/ritonavir compared&#xD;
      to historical controls and by intrapatient comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics on week 0,4,8 and 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of lipid lowering activity on week 0,4,8,12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial function will be measured at week 0 &amp; 12 (optional for patients from Leiden and Nijmegen)</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  use of lopinavir 400mg/ritonavir 100mg bid &gt; 3months&#xD;
&#xD;
          -  HIV-1 RNA &lt;400cop/mL&#xD;
&#xD;
          -  fasting total cholesterol &gt; 6.2mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of sensitivity/idiosyncrasy to the drug or compounds used&#xD;
&#xD;
          -  history or current condition that might interfere with absorption,distribution&#xD;
             metabolism or excretion&#xD;
&#xD;
          -  pregnant or breast-feeding&#xD;
&#xD;
          -  serum transaminase levels &gt;3 times upper limit of normal, creatinine clearance&#xD;
             &lt;60ml/min&#xD;
&#xD;
          -  fasting plasma triglycerides level &gt;8.0 mmol/L&#xD;
&#xD;
          -  history of statin-related rhabdomyolysis or inheritable muscle diseases in family&#xD;
             history&#xD;
&#xD;
          -  clinical symptoms of myopathy or abnormal CK level&#xD;
&#xD;
          -  change in antiretroviral medication within the 3 months immediately preceding first&#xD;
             dose of rosuvastatin&#xD;
&#xD;
          -  use of any statin or fibrate within 6 weeks immediately preceding first dose of&#xD;
             rosuvastatin&#xD;
&#xD;
          -  concomitant use of medications that interfere with rosuvastatin or lopinavir&#xD;
             pharmacokinetics&#xD;
&#xD;
          -  active hepatobiliary or hepatic disease&#xD;
&#xD;
          -  hypothyroidism&#xD;
&#xD;
          -  alcohol abuse&#xD;
&#xD;
          -  japanese or chinese patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Burger, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>van der Lee M, Sankatsing R, Schippers E, Vogel M, Fätkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Bäumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12(7):1127-32.</citation>
    <PMID>18018771</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

